Detailed price information for Aurinia Pharm Ord (AUPH-Q) from The Globe and Mail including charting and trades.

Detailed price information for Aurinia Pharm Ord (AUPH-Q) from The Globe and Mail including charting and trades.

Q3 2025 Earnings Call Transcript November 4, 2025 Aurinia Pharmaceuticals Inc. beats earnings expectations. Reported EPS is ...

Aurinia Pharmaceuticals (AUPH) has swung into profitability over the past year, with earnings climbing at an impressive 43.8% per year on average for the past five years. Investors have watched as ...

Aurinia Pharmaceuticals (($AUPH)) has held its Q3 earnings call. Read on for the main highlights of the call. Aurinia Pharmaceuticals’ recent ...

Aurinia Pharmaceuticals Inc (AUPH) reports significant growth in Lupkynis sales and raises its 2025 sales guidance, while navigating legal and regulatory hurdles.

The resignation of head drug regulator George Tidmarsh comes amid concerns about conduct related to the lupus nephritis drug ...

Aurinia's Q3 2025 saw 27% LUPKYNIS sales growth and raised 2025 guidance. Discover key earnings insights, clinical updates, and pipeline progress.

Aurinia Pharmaceuticals (AUPH) stock gains as the company's Q3 2025 results beat forecasts despite an FDA information request ...